This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (COMPONENT)

This study has been completed.
Information provided by:
4SC AG Identifier:
First received: November 9, 2009
Last updated: February 29, 2012
Last verified: February 2012
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of SC12267 (4SC-101, 35 mg) in combination with methotrexate in comparison to methotrexate alone in the treatment of patients suffering from Rheumatoid Arthritis.

Condition Intervention Phase
Rheumatoid Arthritis Drug: SC12267 (4SC-101) Drug: Placebo Drug: Methotrexate Drug: Folic Acid Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis

Resource links provided by NLM:

Further study details as provided by 4SC AG:

Primary Outcome Measures:
  • Efficacy of SC12267 (4SC-101) in combination with methotrexate in patients with RA [ Time Frame: 13 weeks ]

Secondary Outcome Measures:
  • Evaluation of the safety of the combination of SC12267 (4SC-101) and methotrexate in patients with RA [ Time Frame: 13 weeks ]
  • Evaluation of the plasma concentration (trough value) of SC12267 (4SC-101) after once daily application in combination with methotrexate after once weekly administration. [ Time Frame: 13 weeks ]

Enrollment: 266
Study Start Date: November 2009
Study Completion Date: July 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SC12267 (4SC-101) + Methotrexate Drug: SC12267 (4SC-101)
oral administration
Drug: Methotrexate
oral administration
Drug: Folic Acid
oral administration
Placebo Comparator: Placebo + Methotrexate Drug: Placebo
oral administration
Drug: Methotrexate
oral administration
Drug: Folic Acid
oral administration


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Patients with active RA of functional classes I, II or III according to the criteria of American Rheumatism Association for RA
  • DAS28(ESR) ≥ 4.5 (DAS28 formula with 4 variables using ESR)
  • Patients who have received weekly doses of MTX (10-25 mg/week) for a minimum of 3 months prior to Day 1 dosing, and who have received a stable MTX dose of 10-25 mg/week without any change in route or change in folic acid supplementation for at least 6 weeks prior to Day 1 dosing
  • Patients may receive up to 10 mg/day of oral prednisolone or steroid equivalent. Dose must have been stable for at least 30 days and must not be changed during the washout, screening and treatment periods, unless dictated by tolerability requirements

Main Exclusion Criteria:

  • Patients with RA of functional classes IV according to the criteria of American Rheumatism Association for RA
  • Patients who have received any of the following treatments must abide by the indicated washout period:

    1. Leflunomide requires a 6 month washout period prior to Day 1 dosing
    2. Oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day washout period prior to Day 1 dosing
    3. Cyclosporine, abatacept, etanercept, adalimumab, infliximab, and rituximab require a 60 day washout period prior to Day 1 dosing
    4. Cyclophosphamide requires a 180 day washout period prior to Day 1 dosing
    5. Parenteral or intra-articular corticosteroids require a 30 day washout period prior to Day 1 dosing
  • Receipt of the following drugs within 4 weeks prior to dosing:

    1. Sulfasalazine
    2. Hydroxychloroquine
    3. Use of corticosteroids > 10 mg/day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01010581

MHAT "Kaspela" Department of Rheumatology
Plovdiv, Bulgaria
Diagnostic Consulting Centre "Sv. Anna"
Sofia, Bulgaria
Military Medical Academy
Sofia, Bulgaria
National Multiprofile Transport Hospital "Tsar Boris III" Internal Clinic
Sofia, Bulgaria
UMHAT "Sveti Ivan Rilski"
Sofia, Bulgaria
Czech Republic
Rheumatology Outpatient Clinic
Hlučín, Czech Republic
Diagnostic Center Mediscan
Praha 11, Czech Republic
Institute of Rheumatology
Praha, Czech Republic
Centrum Miriada, Prywatny Gabinet Specjalistyczny
Białystok, Poland
Mazowieckie Centrum Badań Klinicznych s.c.
Grodzisk Mazowiecki, Poland
Śląskie Centrum Osteoporozy
Katowice, Poland
Specjalistyczny Ośrodek ALL-MED
Kraków, Poland
NZOZ Reumed
Lublin, Poland
Prof. Dr Hab. n. m. Leszek Szczepański
Lublin, Poland
Poznański Ośrodek Medyczny NOVAMED
Poznań, Poland
Wojewódzki Szpital Reumatologiczny
Sopot, Poland
NZOZ "Nasz Lekarz"
Toruń, Poland
Centrum Leczenia Chorób Cywilizacyjnych Sp. z o. o. S. K. A.
Warszawa, Poland
Centrum Medyczne Osteomed NZOZ Lecznica Specjalistów
Warszawa, Poland
NZOZ Materia Medica
Wrocław, Poland
Clinic Hospital Sf. Maria
Bucharest, Romania
Emergency Hospital "Prof. Dr. Gerota"
Bucharest, Romania
SC Duomedical
Bucharest, Romania
SC Ianuli Med Consult
Bucharest, Romania
County Hospital Cluj - Rheumatology clinic
Cluj Napoca, Romania
Clinical County Hospital of Targoviste
Targoviste, Dambovita, Romania
Private Practice Prof. Dr. Mioara Banciu
Timisoara, Romania
Sponsors and Collaborators
Principal Investigator: Stanisław Sierakowski, Prof. MD Centrum Miriada, Prywatny Gabinet Specjalistyczny, Bialystok, Poland
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT01010581     History of Changes
Other Study ID Numbers: SC12267-5-2009
Study First Received: November 9, 2009
Last Updated: February 29, 2012

Keywords provided by 4SC AG:
Rheumatoid Arthritis
Phase II

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Folic Acid
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Vitamin B Complex
Growth Substances processed this record on September 19, 2017